The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract that affect millions of people in the United States of America. Among patients with IBD, symptomatic flares are quite common; up to 40-50% of patients in some populations report having a flare at least once per month. For most patients with IBD flares, the typical outpatient treatment consists of corticosteroids and, in some instances, initiation of or switching between 5-aminosalicylic acid-acid preparations, immunomodulators, or biologics. These treatments, while often effective, can have harmful side effects, especially when used for long durations of time. Therefore, alternative treatments are highly sought after by both patients and providers.

NCT Number	NCT07143188
Lead Sponsor	Wake Forest University Health Sciences Collaborators: mBIOTA
Conditions	Inflammatory Bowel Disease
Enrollment	42 participants
Start Date	2026-09
Primary Completion	2027-01 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-29